Following the publication of this article, the authors realized that the published version of Fig. 4A contained an erroneous label; essentially, the information purported to relate to experiments having been performed with docetaxel should not have been included in this figure. The correctly labelled version of Fig. 4 is shown with the remainder of Fig. 4 on the next page. This change does not affect the data shown in the paper, and the text in the published article did accurately describe the information shown in this figure. The authors sincerely apologize for the error that was introduced during the preparation of this figure, and thank the Editor for allowing them the opportunity to publish a Corrigendum. Furthermore, they regret any inconvenience caused. [the original article was published in Oncology Reports 46: Article no. 138, 2021; DOI: 10.3892/or.2021.8089].

中文翻译：

---

[勘误] HORMAD1 通过增强 DNA 损伤耐受性促进三阴性乳腺癌的多西紫杉醇耐药。

在这篇文章发表后，作者意识到图 4A 的已发表版本包含一个错误的标签；从本质上讲，本图中不应包含声称与使用多西紫杉醇进行的实验相关的信息。图 4 的正确标记版本与图 4 的其余部分一起显示在下一页。这一变化不影响论文中显示的数据，已发表文章中的文字确实准确地描述了该图中显示的信息。作者对在准备此图过程中出现的错误表示诚挚的歉意，并感谢编辑给予他们发表勘误的机会。此外，他们对造成的任何不便表示遗憾。[原文章发表在肿瘤学报告 46：文章编号。138, 2021; 内政部：